Analysts’ scores for Concord Biosciences Hldgs (NASDAQ: HRMY) during the last quarter fluctuate from bullish to bearish, as supplied by 6 analysts.

Summarizing their latest assessments, the desk beneath illustrates the evolving sentiments previously 30 days and compares them to the previous months.

Analysts present deeper insights by way of their assessments of 12-month value targets, revealing a mean goal of $45.0, a excessive estimate of $55.00, and a low estimate of $35.00. A unfavourable shift in sentiment is obvious as analysts have decreased the common value goal by 18.48%.

Diving into Analyst Scores: An In-Depth Exploration

A complete examination of how monetary consultants understand Concord Biosciences Hldgs is derived from latest analyst actions. The next is an in depth abstract of key analysts, their latest evaluations, and changes to scores and value targets.

Key Insights:

• Motion Taken: Responding to altering market dynamics and firm efficiency, analysts replace their suggestions. Whether or not they ‘Preserve’, ‘Elevate’, or ‘Decrease’ their stance, it signifies their response to latest developments associated to Concord Biosciences Hldgs. This provides perception into analysts’ views on the present state of the corporate.
• Ranking: Analysts assign qualitative assessments to shares, starting from ‘Outperform’ to ‘Underperform’. These scores convey the analysts’ expectations for the relative efficiency of Concord Biosciences Hldgs in comparison with the broader market.
• Worth Targets: Gaining insights, analysts present estimates for the longer term worth of Concord Biosciences Hldgs’s inventory. This comparability reveals developments in analysts’ expectations over time.

Understanding these analyst evaluations alongside key monetary indicators can supply useful insights into Concord Biosciences Hldgs’s market standing. Keep knowledgeable and make well-considered selections with our Scores Desk.

Keep updated on Concord Biosciences Hldgs analyst scores.

If you’re desirous about following small-cap inventory information and efficiency you can begin by monitoring it right here.

Delving into Concord Biosciences Hldgs’s Background

Concord Biosciences Holdings Inc is a commercial-stage pharmaceutical firm targeted on creating and commercializing therapies for sufferers residing with uncommon neurological illnesses who’ve unmet medical wants. The corporate’s product WAKIX (pitolisant) is a molecule with a novel mechanism of motion particularly designed to extend histamine signaling within the mind by binding to H3 receptors and is used for the remedy of cataplexy in grownup sufferers with narcolepsy. The opposite drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), amongst others.

Concord Biosciences Hldgs: Delving into Financials

Market Capitalization Views: The corporate’s market capitalization falls beneath trade averages, signaling a comparatively smaller dimension in comparison with friends. This positioning could also be influenced by components corresponding to perceived progress potential or operational scale.

Income Progress: Concord Biosciences Hldgs displayed optimistic leads to 3M. As of 30 June, 2025, the corporate achieved a strong income progress price of roughly 16.01%. This means a notable improve within the firm’s top-line earnings. As in comparison with rivals, the corporate encountered difficulties, with a progress price decrease than the common amongst friends within the Well being Care sector.

Internet Margin: Concord Biosciences Hldgs’s monetary energy is mirrored in its distinctive web margin, which exceeds trade averages. With a exceptional web margin of 19.84%, the corporate showcases sturdy profitability and efficient value administration.

Return on Fairness (ROE): Concord Biosciences Hldgs’s ROE surpasses trade requirements, highlighting the corporate’s distinctive monetary efficiency. With a powerful 5.33% ROE, the corporate successfully makes use of shareholder fairness capital.

Return on Property (ROA): The corporate’s ROA is a standout performer, exceeding trade averages. With a powerful ROA of 3.68%, the corporate showcases efficient utilization of property.

Debt Administration: Concord Biosciences Hldgs’s debt-to-equity ratio is beneath trade norms, indicating a sound monetary construction with a ratio of 0.22.

What Are Analyst Scores?

Throughout the area of banking and monetary programs, analysts focus on reporting for particular shares or outlined sectors. Their work entails attending firm convention calls and conferences, researching firm monetary statements, and speaking with insiders to publish “analyst scores” for shares. Analysts sometimes assess and price every inventory as soon as per quarter.

Analysts might improve their evaluations by incorporating forecasts for metrics like progress estimates, earnings, and income, delivering further steering to buyers. It’s vital to acknowledge that, though consultants in shares and sectors, analysts are human and categorical their opinions when offering insights.

Which Shares Are Analysts Recommending Now?

Benzinga Edge provides you immediate entry to all main analyst upgrades, downgrades, and value targets. Kind by accuracy, upside potential, and extra. Click on right here to remain forward of the market.

This text was generated by Benzinga’s automated content material engine and reviewed by an editor.